72922-61-3

Usage

Uses

Used in Pharmaceutical Industry:
4-NITRO-6-INDAZOLECARBOXYLIC ACID METHYL ESTER is used as a precursor in the synthesis of novel pharmaceutical compounds for its potential biological activities and pharmacological properties.
Used in Anticancer Applications:
4-NITRO-6-INDAZOLECARBOXYLIC ACID METHYL ESTER is used as an anticancer agent for its potential to target and inhibit the growth of cancer cells, making it a promising candidate for further research and development in cancer treatment.
Used in Antimicrobial Applications:
4-NITRO-6-INDAZOLECARBOXYLIC ACID METHYL ESTER is used as an antimicrobial agent for its potential to combat various types of bacteria and other microorganisms, contributing to the development of new antimicrobial drugs.
Used in Medicinal Chemistry Research:
4-NITRO-6-INDAZOLECARBOXYLIC ACID METHYL ESTER is used as a valuable candidate in medicinal chemistry research for its unique chemical structure and properties, which can be further explored and optimized for various therapeutic applications.

InChI:InChI=1/C9H7N3O4/c1-16-9(13)5-2-7-6(4-10-11-7)8(3-5)12(14)15/h2-4H,1H3,(H,10,11)

Upstream product

• 54591-62-7 3-amino-4-methyl-5-nitrobenzoic acid 
• 67-56-1 methanol 
• 16533-71-4 3,5-dinitro-p-toluic acid 
• 72922-60-2 methyl 3-amino-4-methyl-5-nitrobenzoate 

Downstream Products

• 885518-51-4 C₉H₉N₃O₂ 

Relevant academic research and scientific papers

Compound with dual inhibitory activity TDO, IDOO1 and application of compound for treating neurodegenerative disease (by machine translation)

The present invention provides a compound of formula I, or a pharmaceutically acceptable salt thereof, or a solvate thereof, which can selectively inhibit TDO, IDOO1, which has a significant inhibitory effect on TDO and/or IDOO1. In addition, the prepared compound has a remarkable anti-tumor effect, has a certain treatment effect on's disease and's disease, and has a good application prospect in the field of medicine preparation. (by machine translation)

Second generation of BACE-1 inhibitors. Part 1: The need for improved pharmacokinetics

Inhibition of the aspartyl protease BACE-1 has the potential to deliver a disease-modifying therapy for Alzheimer's disease. We have recently disclosed a series of transition-state mimetic BACE-1 inhibitors showing nanomolar potency in cell-based assays.

HYDROXYETHYLAMINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE

The present invention relates to novel hydroxyethylamine compounds of formula (I): (I) having Asp2 (-secretase, BACE1 or Memapsin) inhibitory activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases characterised by elevated-amyloid levels or-amyloid deposits, particularly Alzheimer's disease.